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Objective: to compare the ability of two independent Chlamydia pneumoniae antibody tests to predict need for small
abdominal aortic aneurysm (AAA) repair.
Patients and methods: annual scans were offered to 149 screening diagnosed small AAA (<5 cm). Serum samples were
collected for measuring IgA and IgG-antibodies to C. pneumoniae by microimmunofluorescence (MIF) test and the new
ELISA (Labsystems).
Results: a significant concordance was found between MIF and ELISA titres with Kappa values of 0.29 for S-IgA and
0.42 for S-IgG. IgG antibodies measured by ELISA were most predictive for cases expanding operation recommendable
sizes with a sensitivity and specificity of 80% and 66%, respectively.
Conclusion: the simpler EIA has a high correlation with the MIF test and both were predictive for the natural history
of AAA. Chlamydia antibody test may be used to identify individuals who might benefit from follow-up and anti-
chlamydia treatment.
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Introduction 4165 (76.1%) attended. An AAA was defined as an
anteroposterior aortic diameter of [30 mm or more.
AAAs of 5 cm or more were referred to a vascularAn association between Chlamydia pneumoniae, athero-
surgeon. AAAs of 3–4.9 cm were offered yearly follow-sclerosis, and the risk of acute myocardial infarction
up examinations.18,19has been shown in several seroepidemiological stud-
One-hundred-and-seventy men had AAA (4.0%), ofies.1–6 Both DNA and antigens specific for C. pneumoniae
which 21 were >5 cm. Of the remaining 149 cases, 139have been found in atherosclerotic lesions and ab-
(93.3%) have been followed for 1–5 years. Of these, 134dominal aortic aneurysms (AAA).7–14
had serum samples taken at baseline for assessment ofWe previously showed an association between anti-
anti-chlamydial antibodies. Finally, 35 cases of thosebodies to C. pneumoniae and the expansion rate of
having serum samples taken have expanded to >5 cmsmall AAA.15–17 The expansion and rupture of AAA
and been referred for operative evaluation.might therefore be reduced by anti-chlamydial treat-
Serum samples were tested for IgA and IgG anti-ment. In this study we assessed the ability of two
bodies against C. pneumoniae using the conventionalindependent C. pneumoniae serological tests to predict
microimmunofluorescence (MIF) test20 and a new com-the expansion of small AAA.
mercially available ELISA (Labsystems (LOY-EIA)).
The LOY-EIAs for C. pneumoniae IgG and IgA are
indirect solid-phase enzyme immunoassays with
Patients and Methods horseradish peroxidase as a marker enzyme. The test
procedure was as follows: 5 l of serum sample is
Between 1994 and 1996, 5470 65–73 year-old males diluted in dilution buffer 1:100. Ten l of sample di-
were invited for AAA ultrasound screening. Of these, lution were added to the wells coated with C. pneu-
moniae membrane preparation antigen and 100 l of
the sample diluent were added. The plates were in-∗ Please address all correspondence to: S. Vammen, Jyllands Alle
131, 8260 Viby J, Denmark. cubated at 37 °C for 1 h and the residual sample was
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Table 1. The cross table of the IgA titres against Chlamydia pneumoniae Table 2. The cross table of the IgG titres against Chlamydia pneumoniae
measured with the ELISA method and the MIF method with themeasured with the ELISA method and the MIF method with the
consequently significant calculated Kappa value. consequently significant calculated Kappa value.
MIF 0 16 32 64 128 [256MIF 0 16 32 [64
ELISA ELISA
0 16 0 0 2 2 10 44 15 6 5
16 3 12 13 5 16 5 3 1 0 0 0
32 10 1 17 4 1 032 0 1 6 21
[64 0 0 0 3 64 1 1 9 18 6 0
128 0 0 0 6 12 13
[256 0 0 0 0 0 5Kappa value: 0.29 (p<0.01). Mann–Whitney rank sum test (paired
data): p=0.07.
Kappa value: 0.42 (p<0.01). Mann–Whitney rank sum test (paired
data): p=0.47.removed by washing five times with the PBS-Tween
20 washing solution. The corresponding conjugate Table 3. Spearman rank correlation test matrix for IgA and IgG
was added and the plates were incubated as above. antibody titres against Chlamydia pneumoniae measured by both the
ELISA and MIF method.Unbound conjugate was then washed off and a hy-
drogen peroxide with the TMB chromogen was added. ELISA IgA MIF IgA
The colour formation reaction was terminated by add- titre titre
ing sulphuric acid. The colour intensity was measured
ELISA IgG 0.61 0.55at 450 nm. The results are expressed as enzyme im- Titre p<0.01 p<0.01
munounits (EIU), which were calculated as: EIU= MIF IgG 0.57 0.72
Titre p<0.01 p<0.01(Absorption for sample minus absorption for blank)
divided by (absorption for calibrator minus absorption
for blank) times a factor “N”. For the IgG test “N” is
130 and for the IgA test “N” is 30. Using these factors
the EIU value represents the titres of IgG and IgA,
respectively, and the results obtained by the ELISA
test are thereby quantifiable. Samples showing EIU
values exceeding the EIU of the positive control were
prediluted at 1:200–1:400 the dilution factor being
considered when the final EIUs are calculated.
SPSS 10.0 was used for Kappa calculations, Spear-
man’s rank correlation tests, Mann–Whitney test for
paired data, and elaboration of ROC curves. For ana-
lyses of the ROC curves the null hypothesis was that
the test had a performance similar to the diagonal line,
i.e. the area under the curve was 0.5.
Results
Fig. 1. ROC curve for prediction of cases of small abdominal aortic
aneurysm expanding to operation recommendable dimensions with
In order to validate the reproducibility of the measure- iga antibodies against Chlamydia pneumoniae measured by micro-
immunofluourescence test (MIF) and LOY-EIA test.ment of the AAA diameter, 24 patients were measured
twice; 95% of the second measurements were less
than 2 mm different from the first.21 The mean annual and the LOY-test. It therefore seemed that both tests
were measuring the same but with some differences.expansion rate was 2.7 (range 0–9.7) mm/year for the
total population. In addition to the correlation between the tests also a
correlation between the IgA titres and IgG titres wasThe comparability of the results obtained by Lab-
systems EIA test (LOY-EIA) with these of the con- found. This was observed for both the MIF-test and
the LOY-EIA test (Table 3).ventional MIF-test are shown in Tables 1 and 2 for
IgA and IgG, respectively. Kappa values for both IgA In Figures 1 and 2, the ROC curves for predicting
elective surgery are shown for IgA and IgG-antibodies,(0.29) and IgG (0.42) were statistically significant. The
Mann–Whitney’s rank sum test for paired data re- respectively. For both LOY-EIA and MIF test, the IgA
and IgG antibodies were both predictive for AAAvealed no significant differences between the MIF test
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for S-IgG obtained by the EIA (Fig. 2) with a sensitivity
of 80% and a specificity of 66%, respectively.
In contrast to the EIA, the MIF test requires highly
skilled personnel. Based on these findings, the cheaper
and less laborious EIA may replace the MIF test for
detection of C. pneumoniae antibodies. However, from
this study we are not able to assess as to whether the
tests in fact also detect a C. pneumoniae infection,
because as of today no test allow to discriminate
whether or not an individual is or has been infected
with C. pneumoniae, i.e. no true reference standard
exists.22–24 The correlation between demonstrating C.
pneumoniae DNA or antigen in tissue from aneurysms
or plaque material and the antibody titres in serum is
controversy.25,26 Consequently, better characterisation
of the pathogenicity-related antigens and their sub-
sequent production for diagnostic assays is apparentlyFig. 2. ROC curve for prediction of cases of small abdominal aortic
needed. It is however assumed that IgM antibodiesaneurysm expanding to operation recommendable dimensions with
igg antibodies against Chlamydia pneumoniae measured by micro- are not detectable in reinfections and persistent in-
immunofluorescence test (MIF) and LOY-EIA test. fections2,25 for which reason we only assessed IgA and
IgG antibodies.
To evaluate the clinical significance of the resultscases expanding to a size where planned surgery is
obtained by the two tests we assessed the specificityrecommended according to international guidelines.
and sensitivity for various cut-off titres in predictingFor IgA antibodies (Fig. 1), the best predictive value
cases expanding to operation recommendable sizes.was noticed with the MIF test. The MIF test had an
By using a cut-off level of the EIA- IgG titre ofarea under the curve of 0.64 (95% CI, 0.54–0.74), and
1:48, a sensitivity of 80% with a specificity of 66% inan optimal cut-off titre of 1:24 with a sensitivity and
predicting operation could be reached. The EIA-IgGspecificity of 55% and 63%, respectively. The IgA of
titre may thus indicate whom to follow with regularthe LOY-EIA had an area under the curve of 0.61 (95%
ultrasound scans to plan for elective surgery andCI, 0.50–0.72).
whom to include in studies on anti-microbial therapyThe IgG of the MIF test (Fig. 2) had an area under
assuming C. pneumoniae plays a role and the expansionthe curve of 0.60 (95% CI, 0.50–0.71). The best pre-
could be reduced by treating the infection.dictive value was observed for IgG antibodies meas-
Present findings strengthen the theory that C. pneu-ured by the LOY-EIA with an area under the curve of
moniae is involved in AAA expansion. Halme et al.270.66 (95% CI, 0.56–0.76). The optimal cut-off titre was
have shown presence of C. pneumoniae specific T lym-1:48 with a sensitivity and specificity of 80% (28 of 35
phocytes in the AAA wall. This suggests that C. pneu-patients offered surgery had antibodies) and 66% (65
moniae participates in the maintenance of theof 99 patients not offered surgery had a negative test),
inflammatory response in the tissue and thus may berespectively. The predictive values for IgG were 45%
involved in the progression of the disease. However,and 90% for positive and negative test, respectively.
the correlation could also be explained by the factNo correlation between S-IgA antibody negative
that severe atherosclerotic individuals have higher(test titre <1:24) or S-IgG antibody negative (test titre
aneurysmal expansion rates, and that the titre simply<1:48) and S-IgA or S-IgG positive and initial aneurysm
reflects the extend of atherosclerosis as previouslysize, smoking, hospital admittance for atherosclerotic
found.19,26,29 However, in this observational follow-updisease, concomitant lower extremity atherosclerosis,
study we were not able to show a correlation betweenor angina pectoris was found.
IgG or IgA titres and atherosclerotic manifestations
or hospital admittance due to atherosclerotic disease.
These findings are in agreement with the fact that no
Discussion prospective studies so far could demonstrate co-
existing atherosclerosis as a risk factor for expansion.
We found a significant concordance between the results Rather on the contrary; lower ankle blood pressure
obtained of MIF and ELISA and both tests predicted has been associated to aneurysmal lower expansion
rate.30expansion. The best diagnostic performance was found
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